Bruce Binkowitz Joins Arcutis as Vice President of Biometrics
23 August 2021 - 10:00PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations to address the urgent needs of patients living with
immune-mediated dermatological diseases and conditions, or
immuno-dermatology, today announced that Bruce Binkowitz has joined
as Vice President of Biometrics. Dr. Binkowitz, who brings over 30
years of drug development experience, will lead all biometrics
activities for the company including supporting late-stage clinical
programs and regulatory submissions of topical roflumilast in
psoriasis, atopic dermatitis, and seborrheic dermatitis.
“We are pleased to welcome Bruce to Arcutis. He is an
experienced leader who will play an instrumental role as we advance
multiple pivotal clinical studies and our upcoming submission of
our first New Drug Application for roflumilast cream,”
said Frank Watanabe Arcutis’ President and Chief Executive
Officer.
“Arcutis is making a real difference by advancing novel
treatments for serious skin disorders where little progress has
been made in decades,” Dr. Binkowitz said. “I am excited to join
the experienced medical and regulatory team and further clinical
programs across our seven therapeutic areas.”
Most recently, Dr. Binkowitz was the Vice President of
Biometrics at Shionogi, Inc., after spending over 30 years at Merck
and Co. He has worked across all phases of drug development
and across many therapeutic areas including dermatology, oncology,
respiratory, metabolism/diabetes, cardiovascular and ophthalmology.
Dr. Binkowitz has presented at all the major statistics conferences
and has publications spanning more than 30 years, including his
contributions as a thought leader on the topic of multiregional
clinical trials. Dr. Binkowitz is a Fellow of the American
Statistical Association (ASA), and was the 2020 Chair and is
current Past-Chair of the Biopharmaceutical Section of the ASA. Dr.
Binkowitz has a Ph.D. in Quantitative Methodology from the Rutgers
School of Public Health, and a Master’s degree in Statistics from
the University of Florida.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of patients
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis harnesses our unique dermatology
development platform coupled with our dermatology expertise to
build differentiated therapies against biologically validated
targets. Arcutis’ dermatology development platform includes a
robust pipeline with seven clinical programs for a range of
inflammatory dermatological conditions, with our first NDA
submission anticipated by the end of 2021 and three more Phase 3
clinical data readouts anticipated over the next 18 months. The
company’s lead product candidate, topical roflumilast, has the
potential to advance the standard of care for plaque psoriasis,
atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For
more information, visit www.arcutis.com or follow Arcutis
on LinkedIn and Twitter.Forward-Looking
StatementsThis press release contains “forward-looking”
statements, including, among others, statements regarding the
potential for roflumilast to revolutionize the standard of care in
plaque psoriasis and other inflammatory dermatological conditions.
These statements involve substantial known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied by these
forward-looking statements and you should not place undue reliance
on our forward-looking statements. Risks and uncertainties that may
cause our actual results to differ include risks inherent in the
clinical development process and regulatory approval process, the
timing of regulatory filings, and our ability to defend our
intellectual property. For a further description of the risks and
uncertainties applicable to our business, see the “Risk Factors”
section of our Form 10-K filed with U.S. Securities and Exchange
Commission (SEC) on February 16, 2021, as well as any subsequent
filings with the SEC. We undertake no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
805-418-5006
asheldon@arcutis.com
Investors
Eric McIntyre, Head of Investor Relations
805-418-5006
emcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From May 2023 to May 2024